We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans.
- Authors
Jensen, Kevin P; DeVito, Elise E; Herman, Aryeh I; Valentine, Gerald W; Gelernter, Joel; Sofuoglu, Mehmet
- Abstract
Genome-wide association studies have implicated the CHRNA5-CHRNA3-CHRNB4 gene cluster in risk for heavy smoking and several smoking-related disorders. The heavy smoking risk allele might reduce the aversive effects of nicotine, but this hypothesis has not been tested in humans. We evaluated the effects of a candidate causal variant in CHRNA5, rs16969968, on the acute response to nicotine in European American (EA) and African American (AA) smokers (n=192; 50% AA; 73% male). Following overnight abstinence from nicotine, participants completed a protocol that included an intravenous (IV) dose of saline and two escalating IV doses of nicotine. The outcomes evaluated were the aversive, pleasurable, and stimulatory ratings of nicotine's effects, cardiovascular reactivity to nicotine, withdrawal severity, and cognitive performance before and after the nicotine administration session. The heavy smoking risk allele (rs16969968*A; frequency=28% (EA) and 6% (AA)) was associated with lower ratings of aversive effects (P<5 × 10−8) with marked specificity. This effect was evident in EA and AA subjects analyzed as separate groups and was most robust at the highest nicotine dose. Rs16969968*A was also associated with greater improvement on a measure of cognitive control (Stroop Task) following nicotine administration. These findings support differential aversive response to nicotine as one likely mechanism for the association of CHRNA5-CHRNA3-CHRNB4 with heavy smoking.
- Subjects
PHYSIOLOGICAL effects of nicotine; ALKALOIDS; PYRIDINE; TOBACCO; SMOKING; HEALTH
- Publication
Neuropsychopharmacology, 2015, Vol 40, Issue 12, p2813
- ISSN
0893-133X
- Publication type
Article
- DOI
10.1038/npp.2015.131